The purpose of the study is to monitor the clinical safety and performance of the EXCOR Venous Cannula in context of an EXCOR VAD therapy to ensure continued acceptability of identified risks, to enable detecting emerging risks and to assess clinical improvement on both short- and long-term.

The registry study has an observational, prospective, international, multi-center, non-randomized design.

The registry is planned for 42 months (3.5 years), with an enrollment period of 28 months, the follow-up of up to 12 months.

Inclusion Criteria:

• Patient or his/her parent/guardian or legally authorized representative has given the consent by means of a written, signed and dated informed consent form,
• The indications on RVAD and BVAD use of the EXCOR VAD apply,
• Patient shall be on transplant list or at least eligible for HTx,
• BSA (body surface area) greater than or equal to 1.2 m².

Exclusion Criteria:

• Patient or his/her parents/legal guardian or legally authorized guardian has not given the consent,
• The contraindications of EXCOR VAD apply.

Twenty patients with failing/absence of the right heart. The indications on RVAD and BVAD use of the EXCOR VAD apply.